APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication

被引:246
作者
Yu, Q
Chen, D
König, R
Mariani, R
Unutmaz, D
Landau, NR
机构
[1] Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA
[2] Vanderbilt Univ, Dept Microbiol & Immunol, Sch Med, Nashville, TN 37232 USA
关键词
D O I
10.1074/jbc.M408802200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the human genome the apolipoprotein B mRNA-editing enzyme catalytic polypeptide ( APOBEC) 3 gene has expanded into a tandem array of genes termed APOBEC3A-G. Two members of this family, APOBEC3G and APOBEC3F, have been found to have potent activity against virion infectivity factor deficient (Deltavif) human immunodeficiency virus 1 (HIV-1). These enzymes become encapsidated in Deltavif HIV-1 virions and in the next round of infection deaminate the newly synthesized reverse transcripts. The lentiviral Vif protein prevents the deamination by inducing the degradation of APOBEC3G and APOBEC3F. We report here that two additional APOBEC3 family members, APOBEC3B and APOBEC3C, have potent antiviral activity against simian immunodeficiency virus (SIV), but not HIV-1. Both enzymes were encapsidated in HIV-1 and SIV virions and were active against Deltavif SIVmac and SIVagm. SIV Vif neutralized the antiviral activity of APOBEC3C, but not that of APOBEC3B. APOBEC3B induced abundant G --> A mutations in both wild-type and Deltavif SIV reverse transcripts. APOBEC3C induced substantially fewer mutations. APOBEC3F was found to be active against SIV and sensitive to SIVmac Vif. These findings raise the possibility that the different APOBEC3 family members function to neutralize specific lentiviruses.
引用
收藏
页码:53379 / 53386
页数:8
相关论文
共 36 条
  • [11] Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts
    Mangeat, B
    Turelli, P
    Caron, G
    Friedli, M
    Perrin, L
    Trono, D
    [J]. NATURE, 2003, 424 (6944) : 99 - 103
  • [12] A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to vif action
    Mangeat, B
    Turelli, P
    Liao, SY
    Trono, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (15) : 14481 - 14483
  • [13] Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif
    Mariani, R
    Chen, D
    Schröfelbauer, B
    Navarro, F
    König, R
    Bollman, B
    Münk, C
    Nymark-McMahon, H
    Landau, NR
    [J]. CELL, 2003, 114 (01) : 21 - 31
  • [14] Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway
    Mehle, A
    Strack, B
    Ancuta, P
    Zhang, CS
    McPike, M
    Gabuzda, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (09) : 7792 - 7798
  • [15] Recent insights into HIV-1 Vif
    Navarro, F
    Landau, NR
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2004, 16 (04) : 477 - 482
  • [16] Onishi M, 1996, EXP HEMATOL, V24, P324
  • [17] HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells
    Oswald-Richter, K
    Grill, SM
    Shariat, N
    Leelawong, M
    Sundrud, MS
    Haas, DW
    Unutmaz, D
    [J]. PLOS BIOLOGY, 2004, 2 (07) : 955 - 966
  • [18] Detecting hypermutations in viral sequences with an emphasis on G→A hypermutation
    Rose, PP
    Korber, BT
    [J]. BIOINFORMATICS, 2000, 16 (04) : 400 - 401
  • [19] CELL-DEPENDENT REQUIREMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VIF PROTEIN FOR MATURATION OF VIRUS-PARTICLES
    SAKAI, H
    SHIBATA, R
    SAKURAGI, J
    SAKURAGI, S
    KAWAMURA, M
    ADACHI, A
    [J]. JOURNAL OF VIROLOGY, 1993, 67 (03) : 1663 - 1666
  • [20] Schröfelbauer B, 2004, AIDS REV, V6, P34